Abstract: Telomere shortening, clonal hematopoiesis and disease risk
This abstract describes how progressive telomere shortening with cell division acts as a biologic clock, and how critically short telomeres with aging can drive clonal hematopoiesis, which is associated with higher risks of cardiovascular disease and cancer. [1]
Automatic summary · not editorially reviewed
The key findings
Progressive telomere shortening with each cell division is described as a biologic clock contributing to limited human lifespan. [1]
Clonal hematopoiesis is described as associated with elevated risks of cardiovascular disease and cancer. [1]
Telomere maintenance and regulation are called promising therapeutic targets for aging, cardiovascular disease and cancer. [1]
The source at a glance
- Study type / format
- Abstract of a review-style discussion of telomere biology
- Population / context
- Human aging biology as described in the abstract; no specific study population is reported.
- Summary based on
- Study abstract
- Original publication
- September 29, 2026
Telomere shortening as a biologic clock
The abstract states that telomeres protect chromosome ends and help preserve genomic integrity. With each cell division, telomeres shorten progressively; the text calls this a biologic clock that contributes to limited human lifespan. When telomeres become critically short with aging, DNA damage responses are activated, leading to cellular senescence or apoptosis. This is a general description of aging biology, not a measured result from a study population.
Supporting source [1]
Clonal hematopoiesis linked to cardiovascular disease and cancer
According to the abstract, critically short telomeres create selective pressure that triggers somatic mutations. Mutant hematopoietic stem cells driving clonal hematopoiesis gain a fitness and survival advantage over normal hematopoietic stem cells. Clonal hematopoiesis is then described as associated with elevated risks of cardiovascular disease and cancer. The text presents these as associations, not as proof that telomere shortening causes these diseases.
Supporting source [1]
TERT promoter mutations and proposed therapeutic targets
In more extreme cases, the abstract says, continued proliferation driven by somatic mutations of p53 and other checkpoint genes, combined with critically short telomeres, can promote mutations in the TERT promoter gene. These mutations reactivate telomerase, enabling sustained proliferation, cellular immortality and malignant transformation. The abstract concludes that telomere maintenance and regulation are promising therapeutic targets for aging, cardiovascular disease and cancer; this is a proposal, not a validated treatment.
Supporting source [1]
How to interpret this
This explainer is based only on the abstract; the full text was not reviewed. The abstract reports no study design, sample size, follow-up or measured outcome data, so the described mechanisms and associations are not quantified here.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zheng H, Zhan H. · europepmc.org · September 29, 2026